Clinical Trials Logo

Clinical Trial Summary

The objective of this study was to evaluate the long-term safety and tolerability of 7-day BTDS in a 28-week open-label extension phase in subjects with chronic nonmalignant pain syndromes whose pain had been previously controlled by oral opioid combination therapy.


Clinical Trial Description

Upon entering the extension phase (BUP3201S), subjects will receive BTDS 5, regardless of their dose level at discontinuation or completion of the BUP3201 core study. Subjects are allowed to titrate after 48 hours to BTDS 10 or 20 that provided stable pain control with minimal tolerability problems. Additional medical therapies are permitted if necessary, and there is no restriction on concomitant analgesic medications. The subjects have weekly visits for 4 consecutive weeks, and every 4 weeks thereafter, until the end of the scheduled extension phase. ;


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01151098
Study type Interventional
Source Purdue Pharma LP
Contact
Status Completed
Phase Phase 3
Start date April 2001
Completion date February 2002

See also
  Status Clinical Trial Phase
Completed NCT04313426 - Chronic Pain Self-Management With Integrative Yoga Therapy (IYT) N/A
Completed NCT04096391 - Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population N/A
Completed NCT03981302 - Family Nursing Conversations Patients With Chronic Non-Cancer Pain N/A
Completed NCT03036917 - Cognitive Function Before and After Opioid Reduction in Patients With Chronic Pain